This bill asks state agencies and law enforcement groups to report on how they are using opioid settlement funds for treatment and prevention programs in correctional facilities. It also requests that the Opioid Abatement Task Force and the Attorney General provide clearer guidance on which expenses are allowed under these funds. The measure aims to address concerns raised in a recent audit that many local areas have not spent their allocated money due to confusion about rules and a lack of available programs. By gathering this information, the state hopes to ensure that the millions of dollars received from opioid lawsuits are used effectively to help incarcerated individuals with substance use disorders.
This bill prohibits the manufacture, sale, transfer, and possession of devices used to program or emulate motor vehicle keys and relay attack devices, which intercept key fob signals to unlock or start cars. The law applies to individuals and businesses but includes exceptions for law enforcement, insurance investigators, licensed automotive professionals, locksmiths, and repossession agencies. Authorized users must report lost or stolen devices to law enforcement within 48 hours, with violations punishable by fines up to $1,000 or up to six months in prison. The legislation aims to prevent unauthorized access to vehicles while allowing legitimate professionals to continue their work.
This bill protects healthcare providers and individuals from civil and criminal liability when they distribute or use Naloxone and other opioid reversal drugs even after their labeled expiration dates have passed. It allows people acting in good faith to administer these medications to someone believed to be having an opioid overdose without fear of legal consequences, except in cases of gross negligence or intentional misconduct. Healthcare professionals are also shielded from disciplinary action by licensing boards for actions covered under this immunity, though federally certified facilities must still follow federal rules regarding expired medications. The law defines "shelf-life end date" based on federal labeling requirements and takes effect upon the governor's signature.
SB 118 requires courts to screen all misdemeanor DUI offenders (first and second offenses) for substance use disorder risk as part of probation conditions. It mandates using evidence-based screening tools validated for impaired driving, with results kept confidential and shared directly with the court, prosecutors, and defense counsel. If screening indicates risk, courts may order a full assessment by a licensed clinician to determine if a substance use disorder diagnosis exists. This policy applies to both first and second offense DUI cases under Louisiana law, focusing on early intervention rather than altering penalties.
SB 26 repeals two Louisiana statutes (R.S. 40:2116(B)(5) and 2159) that required facility need reviews for opioid treatment programs. This bill directly affects opioid treatment facilities in Louisiana by removing a specific administrative review requirement. The key change is eliminating the need for these facilities to undergo a separate review process before operating, streamlining their regulatory compliance under state law.
HB 404 establishes a medication-assisted treatment (MAT) program for incarcerated individuals in Louisiana state and local correctional facilities who have substance abuse disorders. The bill requires facilities to provide FDA-approved medications (like methadone or buprenorphine), individual treatment plans, counseling, and reentry support - including Medicaid enrollment assistance, housing/employment resources, and a one-week medication supply upon release. It mandates annual reporting on program effectiveness, including recidivism and health outcomes, and prohibits denying program access based on drug screenings or past disciplinary issues. The program directly affects all incarcerated people in Louisiana facilities with substance use disorders, aiming to improve treatment continuity and reduce relapse post-release.
